PDCD1 and melanoma: This study was performed to obtain post-marketing data on the efficacy of the anti-PD1 monoclonal antibody nivolumab in Japanese patients with advanced melanoma, with the exploratory objective of identifying predictive and/or prognostic factors for efficacy.